Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 13, 2020 (7 years ago)

*Mitomycin 0.04% Ophth DR eye drops

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

*Mitomycin 0.04% Ophth DR eye drops, 5 mL bottle, Rx only, Medical Center Pharmacy, 2401 N. Ocoee Street, Cleveland, TN 37311, NDC 67457-0518-05.

Affected NDC 67457-0518-05

Compare with the code on your package — it is the most precise check available.

Drug: Mitomycin Category: Eye Drops & Ophthalmic

Recalling firm
Medical Center Pharmacy, Inc.
NDC code
67457-0518-05
Origin
TN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1077-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Mitomycin recalls

See all
Class II · Moderate risk

Mitomycin 0.4mg/Ml

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Terminated Sterility / contamination Pharmacy Innovations D-0224-2023
Class II · Moderate risk

Mitomycin 0.2mg/Ml

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Terminated Sterility / contamination Pharmacy Innovations D-0223-2023
Class II · Moderate risk

MITOMYCIN INJECTION 0.375 mg/mL SYR

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0039-2023

Other recalls by Medical Center Pharmacy, Inc.

All 2020 recalls
Class II · Moderate risk

*Morphine 2 mg/mL Cassette

Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.

Terminated Sterility / contamination Medical Center Pharmacy, Inc. NDC 00409-1134-03 D-1075-2020
Class II · Moderate risk

C-*Vancomycin Opthal 14 mg drops

Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.

Terminated Sterility / contamination Medical Center Pharmacy, Inc. NDC 67457-0340-01 D-1074-2020
Class II · Moderate risk

C-*Albumin Eye Drop 10% S

Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.

Terminated Sterility / contamination Medical Center Pharmacy, Inc. NDC 44206-0251-05 D-1073-2020